EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
27/03/2026
Voltar para busca
Dado oficial do USPTO
PROPHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PROPHARMA
ST13
US500000087565861Classe
35, 42, 44, 45
Pedido
87565861
Registro
5522690
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
29/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 42, 44, 45
Data de depósito
11/08/2017
Data de registro
24/07/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/01/2024
Última transação
29/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
702
Cadastro oficial
Principal Register
Primeiro uso
2001-00-00
Primeiro uso no comércio
2001-00-00
Código do desenho
4
Tipo de titular
16
Localização do titular
Raleigh, NC, US
Examinador
SANTOMARTINO, MARTHA L
Unidade examinadora
M30
Localização atual
TMO LAW OFFICE 112
Titulares e representantes
Titulares
ProPharma Group Holdings, LLC
ProPharma Group Holdings, LLC
Representantes
Dianne M. Smith-Misemer HOVEY WILLIAMS LLP
Classificação técnica
Classes Nice
Classe 35Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Business information and business consulting servicesproviding business advisory services to identifyscreenselect contract manufacturing organizations to contract and build medical and pharmaceutical products and devices; providing business advisory services to health care providersdesigning the administrativefinancial and clinical workflows associated with value-based healthcare delivery models; providing business assistance to healthcare providers in the field of enabling communication and collaboration for the purpose of developingimplementing and evaluating patient care plans; Business servicestracking and monitoring regulatory requirements in the pharmaceuticalbiotechnologymedical fields for business purposes
Classe 42
Providing quality assurance services in the medicalpharmaceuticalbiotechnology fields; Quality management servicesquality evaluation and analysisquality assurancequality controlin the medicalpharmaceuticalbiotechnology fields; Testinganalysisevaluation of medicalpharmaceuticalbiotechnology services to assure compliance with industry standards; Tracking and monitoring regulatory requirements in the pharmaceuticalbiotechnologymedical fields for quality control purposes
Classe 44
Consulting services in the medicalpharmaceuticalbiotechnology fields; providing medical and pharmaceutical information servicesdrug interaction call centersadverse event reporting services for drugs and medical devices and product compliant reporting services for drugs and medical device; medical information; providing medical informationconsultancy and advisory services; health care consultingaggregating clinicalclaimssocioeconomic and behavioral health data for the purpose of improving healthcare providers' evaluation of health conditions and health risks with individual patientscohorts of patientspopulations; health care consultingassessing patient and population health profiles using evidence-based medical guidelines for the purpose of improving healthcare provider treatment decisions at the point of care; providing information over a global computer network in the field of health care; maintaining files and records concerning the medical condition of individuals; maintaining personal medical history records and files; providing medical informationconsultancyadvisory servicesproviding healthcare providersinsurance companieshealthcare product manufacturers with information and statistics regarding patient medication intakeschedule compliancehealth status
Classe 45
Regulatory compliance consulting in the pharmaceuticalbiotechnologymedical fields; Regulatory compliance consulting in the fields of drug and device development and manufacturing; Tracking and monitoring regulatory requirements in the pharmaceuticalbiotechnologymedical fields for legal or regulatory compliance purposes; Tracking and monitoring regulatory requirements in the field of drug and device development and manufacturing for regulatory compliance purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/03/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/03/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/03/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/09/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/09/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/09/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
23/09/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
23/09/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
25/01/2024
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
25/01/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
25/01/2024
E815
TEAS SECTION 8 & 15 RECEIVED
02/08/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
24/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
24/07/2018
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
17/06/2018
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
21/02/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/02/2018
PUBO
PUBLISHED FOR OPPOSITION
06/02/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/01/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/12/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
30/12/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/12/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
30/12/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/12/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/12/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
15/11/2017
GNRT
NON-FINAL ACTION E-MAILED
15/11/2017
CNRT
NON-FINAL ACTION WRITTEN
15/11/2017
DOCK
ASSIGNED TO EXAMINER
14/11/2017
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
31/08/2017
ALIE
ASSIGNED TO LIE
31/08/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/08/2017
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
15/08/2017
NWAP
NEW APPLICATION ENTERED
15/08/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PROPHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.